NOVARTIS

Novartis Biomedical Research will collaborate with CAS (American Chemical Society) to standardize and make internal research data on chemical reactions searchable. The goal is a custom search and analysis platform that links Novartis data with the extensive CAS database, facilitating computational analyses and the use of modern AI systems. The initiative is intended to give researchers faster access to information and increase research efficiency; Novartis shares traded slightly lower on the SIX exchange. » More on finanzen.net

A federal judge in Manhattan dismissed a class action against Novartis that accused the company of delaying the market entry of Entresto generics by improperly listing a patent in the FDA's Orange Book. The court found the patent was properly listed in the Orange Book, rejecting the allegation. Neither the plaintiffs nor Novartis have commented on the ruling so far. » More on finanzen.net

The CHMP recommends approval of Cosentyx for the treatment of polymyalgia rheumatica in adults who respond insufficiently to corticosteroids or whose disease flares when tapering corticosteroids. The recommendation is based on the phase‑3 Replenish study, in which Cosentyx doubled the rate of sustained symptom freedom at 52 weeks versus placebo and reduced total corticosteroid dose, with no new safety concerns. If the European Commission confirms the recommendation (usually within two months), Cosentyx would be the first interleukin‑17A inhibitor in Europe for this indication. Novartis shares briefly fell 0.48 percent to 115.46 francs. » More on finanzen.net